Breaking News Instant updates and real-time market news.

VNNVF

Vonovia

$0.00 /

+ (+0.00%)

06:28
04/09/20
04/09
06:28
04/09/20
06:28

Vonovia downgraded to Reduce from Hold at HSBC

HSBC analyst Thomas Martin downgraded Vonovia to Reduce from Hold with a price target of EUR 48, down from EUR 51.30. The analyst notes that the company's rent cash flow stream is relatively resilient and safe, though a higher number of non-payers is likely. In a bear case, Vonovia estimates cash flows impacted by about EUR 40M if 8K of its tenants cannot pay rent for the next 3 months.

VNNVF Vonovia
$0.00 /

+ (+0.00%)

04/03/20 Goldman Sachs
Vonovia price target lowered to EUR 59.80 from EUR 62.10 at Goldman Sachs
03/11/20 Morgan Stanley
Vonovia price target raised to EUR 58 from EUR 52 at Morgan Stanley
03/06/20 Deutsche Bank
Deutsche Bank reiterates Buy on Vonovia after FY19 results
03/06/20 Berenberg
Berenberg backs EUR 54.50 price target on Vonovia

TODAY'S FREE FLY STORIES

General news
Asian Market Update: » 01:40
07/14/20
07/14
01:40
07/14/20
01:40

Asian Market Update: The…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Hot Stocks
Mohawk sinks after disclosing subpoenas from SEC, U.S. attorney » 20:49
07/13/20
07/13
20:49
07/13/20
20:49
MHK

Mohawk

$76.59 /

+6.06 (+8.59%)

Shares of Mohawk…

Shares of Mohawk Industries moved lower after the company disclosed that it received subpoenas issued by the U.S. Attorney's Office for the Northern District of Georgia and the Securities and Exchange Commission on topics similar to those raised in an amended class action complaint. The company is cooperating with the authorities. On June 29, an amended class action complaint for violations of federal securities laws was filed against Mohawk and its CEO Jeff Lorberbaum in the Northern District of Georgia, the company said in a SEC filing. The complaint alleges that the company engaged in fabricating revenues by attempting delivery to customers that were closed and recognizing these attempts as sales, overproduced product to report higher operating margins and maintained significant inventory that was not salable and valued certain inventory improperly or improperly delivered inventory with knowledge that it was defective and customers would return it. Mohawk "intends to vigorously defend itself in the lawsuit." Mohawk added, "As we manage through the current economic disruption, Mohawk is well positioned with a strong balance sheet and limited debt. We have recently issued over $1 billion of long term bonds to strengthen our ability to strategically invest and better position Mohawk for the future. Our operations are improving as countries adapt to Covid-19." Shares of Mohawk are down 5% to $72.99 in after-hours trading.

ShowHide Related Items >><<
MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

07/10/20 Jefferies
Mohawk could see short-lived relief rally after flooring data, says Jefferies
07/09/20 Stifel
Stifel says 'difficult if not impossible to opine' on Mohawk allegations
07/09/20 JPMorgan
Allegations in lawsuit to create overhang on Mohawk shares, says JPMorgan
07/09/20 SunTrust
Mohawk quiet period hinders lawsuit response, says SunTrust
MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

Earnings
Notable companies reporting before tomorrow's open » 20:25
07/13/20
07/13
20:25
07/13/20
20:25
JPM

JPMorgan

$97.66 /

+1.35 (+1.40%)

, C

Citi

$52.25 /

-0.39 (-0.74%)

, WFC

Wells Fargo

$25.43 /

-0.04 (-0.16%)

, FAST

Fastenal

$43.38 /

+0.34 (+0.79%)

, FRC

First Republic

$106.82 /

+1.4 (+1.33%)

, DAL

Delta Air Lines

$27.15 /

+0.05 (+0.18%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include JPMorgan (JPM), consensus $1.04... Citigroup (C), consensus 28c... Wells Fargo (WFC), consensus (20c)... Fastenal (FAST), consensus 36c... First Republic Bank (FRC), consensus $1.17... Delta Air Lines (DAL), consensus ($4.12).

ShowHide Related Items >><<
WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

FRC First Republic
$106.82 /

+1.4 (+1.33%)

FAST Fastenal
$43.38 /

+0.34 (+0.79%)

DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

C Citi
$52.25 /

-0.39 (-0.74%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

07/09/20 Wolfe Research
JPMorgan upgraded to Outperform from Peer Perform at Wolfe Research
07/09/20 DA Davidson
JPMorgan upgraded to Buy from Neutral at DA Davidson
07/08/20 Seaport Global
JPMorgan initiated with a Buy at Seaport Global
06/23/20 Wells Fargo
Finicity should help MasterCard with open banking efforts, says Wells Fargo
C Citi
$52.25 /

-0.39 (-0.74%)

07/08/20 Seaport Global
Citi initiated with a Buy at Seaport Global
07/07/20 Societe Generale
Societe Generale upgrades BofA, Citi to Buy on 'path to respectability'
07/07/20 Societe Generale
Citi upgraded to Buy from Hold at Societe Generale
07/01/20 BofA
BofA makes 14 additions, four deletions from US 1 list
WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

07/10/20 Baird
Wells Fargo upgraded to Outperform from Neutral at Baird
07/09/20 Wolfe Research
Wells Fargo upgraded to Peer Perform from Underperform at Wolfe Research
07/08/20 JPMorgan
Wells Fargo price target lowered to $29.50 from $32 at JPMorgan
07/08/20 Seaport Global
Wells Fargo initiated with a Neutral at Seaport Global
FAST Fastenal
$43.38 /

+0.34 (+0.79%)

07/13/20 Morgan Stanley
Illinois Tool Works downgraded to Underweight at Morgan Stanley
07/02/20 Wells Fargo
Fastenal price target raised to $50 from $45 at Wells Fargo
07/02/20 Deutsche Bank
Fastenal initiated with a Buy at Deutsche Bank
06/23/20
Fly Intel: Top five analyst upgrades
FRC First Republic
$106.82 /

+1.4 (+1.33%)

06/01/20 JPMorgan
First Republic price target raised to $130 from $120 at JPMorgan
05/05/20 Atlantic Equities
Atlantic Equities upgrades First Republic to Neutral on mortgage refi boost
05/05/20 Atlantic Equities
First Republic upgraded to Neutral from Underweight at Atlantic Equities
04/15/20 BMO Capital
First Republic price target raised to $99 from $90 at BMO Capital
DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

07/09/20 Citi
Citi sees expectations for corporate travel rebound all but evaporating
06/29/20 Goldman Sachs
Delta Air Lines price target raised to $38 from $33 at Goldman Sachs
06/16/20 Stifel
United loyalty deal raises odds of survival without restructuring, says Stifel
06/10/20 JPMorgan
Delta Air Lines price target lowered to $41 from $45 at JPMorgan
WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

FRC First Republic
$106.82 /

+1.4 (+1.33%)

FAST Fastenal
$43.38 /

+0.34 (+0.79%)

DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

C Citi
$52.25 /

-0.39 (-0.74%)

  • 15
    Jan
WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

C Citi
$52.25 /

-0.39 (-0.74%)

WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

FAST Fastenal
$43.38 /

+0.34 (+0.79%)

DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

FAST Fastenal
$43.38 /

+0.34 (+0.79%)

DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

C Citi
$52.25 /

-0.39 (-0.74%)

Hot Stocks
Crowdstrike CEO sells $28M in common stock » 20:09
07/13/20
07/13
20:09
07/13/20
20:09
CRWD

Crowdstrike

$106.20 /

-10.36 (-8.89%)

In a regulatory filing,…

In a regulatory filing, Crowdstrike disclosed that its CEO George Kurtz sold 28M in common stock on July 9th.

ShowHide Related Items >><<
CRWD Crowdstrike
$106.20 /

-10.36 (-8.89%)

CRWD Crowdstrike
$106.20 /

-10.36 (-8.89%)

07/09/20 Citi
Crowdstrike upgraded to Neutral on end-point share gains at Citi
07/09/20 Citi
Crowdstrike upgraded to Neutral from Sell at Citi
06/24/20 Goldman Sachs
Crowdstrike price target raised to $107 from $87 at Goldman Sachs
06/12/20 RBC Capital
Crowdstrike price target raised to $115 from $105 at RBC Capital
CRWD Crowdstrike
$106.20 /

-10.36 (-8.89%)

  • 26
    Jun
  • 07
    Jan
  • 09
    Dec
CRWD Crowdstrike
$106.20 /

-10.36 (-8.89%)

CRWD Crowdstrike
$106.20 /

-10.36 (-8.89%)

CRWD Crowdstrike
$106.20 /

-10.36 (-8.89%)

Periodicals
Delta Air Lines may avoid involuntary furlougs this fall, Reuters says » 20:08
07/13/20
07/13
20:08
07/13/20
20:08
DAL

Delta Air Lines

$27.15 /

+0.05 (+0.18%)

Delta Air Lines has…

Delta Air Lines has received interest from over 15,000 employees regarding early exit deals, which may keep the company from announcing involuntary furloughs this fall, Reuters' David Shepardson and Tracy Rucinski report, citing one person with the knowledge of the matter. In order to save costs, the company is also considering extending reduced work hours for employees past September, the report states. Reference Link

ShowHide Related Items >><<
DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

07/09/20 Citi
Citi sees expectations for corporate travel rebound all but evaporating
06/29/20 Goldman Sachs
Delta Air Lines price target raised to $38 from $33 at Goldman Sachs
06/16/20 Stifel
United loyalty deal raises odds of survival without restructuring, says Stifel
06/10/20 JPMorgan
Delta Air Lines price target lowered to $41 from $45 at JPMorgan
DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

DAL Delta Air Lines
$27.15 /

+0.05 (+0.18%)

Earnings
Ryerson sees Q2 revenue $765M-$775M, consensus $761.4M. » 20:05
07/13/20
07/13
20:05
07/13/20
20:05
RYI

Ryerson

$5.30 /

-0.07 (-1.30%)

Sees Q2 adj. EBITDA…

Sees Q2 adj. EBITDA $19M-$21M and net loss of $26M to $28M. The company states: "Early indications for Q3 are seeing a continuation of the recovery initiated in Q2 as average selling prices, gross margins, excluding LIFO and order rates are all currently trending positively. "

ShowHide Related Items >><<
RYI Ryerson
$5.30 /

-0.07 (-1.30%)

RYI Ryerson
$5.30 /

-0.07 (-1.30%)

05/20/20 BMO Capital
Ryerson price target lowered to $6 from $9 at BMO Capital
08/26/19 BMO Capital
Ryerson price target lowered to $7 from $9 at BMO Capital
RYI Ryerson
$5.30 /

-0.07 (-1.30%)

Recommendations
Edwards Lifesciences patent settlement removes overhang, says Piper Sandler » 20:00
07/13/20
07/13
20:00
07/13/20
20:00
EW

Edwards Lifesciences

$67.18 /

-0.67 (-0.99%)

, ABT

Abbott

$93.13 /

+0.09 (+0.10%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder keeps his Overweight rating and $88 price target on Edwards Lifesciences (EW) after its patent settlement, saying the agreement - for which the company will take a pre-tax charge of $368M in Q2, as disclosed on its 8K filing - will remove an overhang from the shares. Maeder adds that while data remains relatively early, Edwards Lifesciences' Pascal device appears to be "highly competitive" with Abbott's (ABT) latest generation of MitraClip devices.

ShowHide Related Items >><<
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

06/05/20 Piper Sandler
Post points to Edwards resuming recruiting for CLASP trial, says Piper Sandler
04/28/20 Wells Fargo
Edwards Lifesciences downgraded on sales growth gap at Wells Fargo
04/28/20 Wells Fargo
Edwards Lifesciences downgraded to Equal Weight from Overweight at Wells Fargo
04/27/20 Barclays
Edwards Lifesciences price target lowered to $155 from $165 at Barclays
ABT Abbott
$93.13 /

+0.09 (+0.10%)

07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
06/15/20 Piper Sandler
Abbott approval narrows competitive gap to DexCom, says Piper Sandler
06/11/20 UBS
Abbott's COVID-19 testing positive contributor, says UBS
06/09/20 Barrington
Surmodics price target raised to $62 from $56 at Barrington
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

ABT Abbott
$93.13 /

+0.09 (+0.10%)

Hot Stocks
Biogen initiates new phase 3 study of BAN2401 in preclinical AD » 19:36
07/13/20
07/13
19:36
07/13/20
19:36
BIIB

Biogen

$276.34 /

-2.71 (-0.97%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

The Alzheimer's…

The Alzheimer's Clinical Trials Consortium and Biogen (BIIB) announced that a new Phase 3 clinical study of BAN2401, an anti-amyloid beta protofibril antibody, has been initiated in the United States of America for individuals with preclinical Alzheimer's disease, or AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains. Currently, BAN2401 is being studied in a pivotal Phase III clinical study in symptomatic early AD, following the outcome of the Phase II clinical study. The AHEAD 3-45 will be conducted in the US, Japan, Canada, Australia, Singapore, and Europe. AHEAD 3-45 is a Phase III clinical study, conducted as a public-private partnership between the ACTC, funded by the National Institute on Aging, part of the National Institutes of Health, and Eisai (ESALY). After a common screening period in AHEAD 3-45, participants will be enrolled into one of two randomized, double-blind, placebo controlled trials based on the level of amyloid in the brain: the A45 trial and the A3 trial. A total of 1400 participants will be enrolled in the study and treated with BAN2401 for 216 weeks.

ShowHide Related Items >><<
ESALY Eisai
$0.00 /

+ (+0.00%)

BIIB Biogen
$276.34 /

-2.71 (-0.97%)

BIIB Biogen
$276.34 /

-2.71 (-0.97%)

07/13/20 Goldman Sachs
Biogen price target lowered to $257 from $300 at Goldman Sachs
07/08/20 Credit Suisse
Biogen submits Aducanumab BLA, upside possible near-term, says Credit Suisse
07/08/20 Stifel
Biogen submission of Aducanumab BLA 'an incremental positive,' says Stifel
07/08/20 Goldman Sachs
Goldman says Biogen BLA submission for Alzheimer's drug an incremental positive
ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
BIIB Biogen
$276.34 /

-2.71 (-0.97%)

BIIB Biogen
$276.34 /

-2.71 (-0.97%)

BIIB Biogen
$276.34 /

-2.71 (-0.97%)

BIIB Biogen
$276.34 /

-2.71 (-0.97%)

Periodicals
SoftBank may list Arm Holdings in IPO as soon as 2021, Bloomberg says » 19:27
07/13/20
07/13
19:27
07/13/20
19:27
SFTBY

SoftBank

$0.00 /

+ (+0.00%)

, GS

Goldman Sachs

$208.93 /

+3.33 (+1.62%)

In a follow-up to an…

In a follow-up to an earlier WSJ report, Bloomberg's Giles Turner and Sarah McBride also write that Softbank (SFTBY) is exploring a sale or an IPO of its Arm Holdings business. Citing people familiar with the matter, Turner and McBride write that if the company pursues a listing, it could go public as soon as 2021. Goldman Sachs (GS) is reported to be advising on the potential deal, Bloomberg states.

ShowHide Related Items >><<
SFTBY SoftBank
$0.00 /

+ (+0.00%)

GS Goldman Sachs
$208.93 /

+3.33 (+1.62%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

07/10/20 Nomura Instinet
SoftBank price target raised to 7,240 yen from 6,640 yen at Nomura Instinet
05/26/20 Citi
SoftBank price target lowered to 7,100 yen from 8,200 yen at Citi
03/24/20 Jefferies
SoftBank upgraded to Buy from Hold at Jefferies
02/13/20 HSBC
SoftBank price target raised to 7,000 yen after Sprint deal approval
GS Goldman Sachs
$208.93 /

+3.33 (+1.62%)

07/08/20 Seaport Global
Goldman Sachs initiated with a Buy at Seaport Global
06/26/20 Morgan Stanley
Morgan Stanley sees dividend cuts at Wells Fargo, Capital One after stress tests
06/05/20 Wells Fargo
Goldman Sachs price target raised to $255 from $230 at Wells Fargo
06/04/20
Fly Intel: Top five analyst downgrades
GS Goldman Sachs
$208.93 /

+3.33 (+1.62%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

GS Goldman Sachs
$208.93 /

+3.33 (+1.62%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

GS Goldman Sachs
$208.93 /

+3.33 (+1.62%)

GS Goldman Sachs
$208.93 /

+3.33 (+1.62%)

Periodicals
U.S. official says COVID-19 vaccine output to start by end of summer, CNBC says » 19:22
07/13/20
07/13
19:22
07/13/20
19:22
BNTX

BioNTech

$77.73 /

+7.315 (+10.39%)

, PFE

Pfizer

$35.22 /

+1.38 (+4.08%)

, INO

Inovio

$25.57 /

+2.21 (+9.46%)

, JNJ

Johnson & Johnson

$145.30 /

+2.85 (+2.00%)

, MRNA

Moderna

$71.72 /

+9.15 (+14.62%)

, SPY

SPDR S&P 500 ETF Trust

$314.80 /

-2.81 (-0.88%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

, NVAX

Novavax

$104.46 /

+10.1 (+10.70%)

, MRK

Merck

$77.38 /

+0.64 (+0.83%)

, SNY

Sanofi

$50.96 /

+0.64 (+1.27%)

, GSK

GlaxoSmithKline

$40.07 /

+0.16 (+0.40%)

A senior Trump…

A senior Trump administration official said that U.S. health officials and drugmakers anticipate starting to make potential COVID-19 vaccine doses by the end of the summer, CNBC's Berkeley Lovelace, Jr. reports. The U.S. is seeking to deliver 300M doses of a coronavirus vaccine by early 2021, and the manufacturing process is already underway even though they aren't sure which vaccine, if any, will be effective, the author says, citing a senior Trump administration official. "Exactly when the vaccine materials will be in production and manufacturing? It's probably four to six weeks away," the official said on a call with reporters, which was hosted by the Department of Health and Human Services. "But we will be actively manufacturing by the end of the summer." Publicly traded companies working on vaccines include Moderna (MRNA), Johnson & Johnson (JNJ), Inovio (INO), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX), Merck (MRK), Sanofi (SNY), and GlaxoSmithKline (GSK). Reference Link

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

07/13/20 Canaccord
BioNTech price target raised to $75 from $60 at Canaccord
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
07/02/20 SVB Leerink
BioNTech price target raised to $42 from $37 at SVB Leerink
PFE Pfizer
$35.22 /

+1.38 (+4.08%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
INO Inovio
$25.57 /

+2.21 (+9.46%)

07/01/20
Fly Intel: Top five analyst downgrades
07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
07/01/20 Roth Capital
Roth 'unimpressed' with Inovio data, downgrades to Sell with $11 target
07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
07/13/20 H.C. Wainwright
Pacira price target raised to $68 from $63 at H.C. Wainwright
07/10/20 Jefferies
Pacira price target raised to $69 from $53 at Jefferies
07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
MRNA Moderna
$71.72 /

+9.15 (+14.62%)

07/13/20 Brookline
Moderna initiated with a Buy at Brookline
07/13/20 Jefferies
Jefferies starts Moderna with Buy rating, $90 price target
07/08/20 Piper Sandler
Piper reiterates $100 target on Moderna after Phase II study enrolled
SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
SPX S&P 500
$0.00 /

+ (+0.00%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

07/08/20
Fly Intel: Top five analyst downgrades
07/08/20 Ladenburg
Novavax downgraded to Neutral from Buy at Ladenburg
07/07/20 Cantor Fitzgerald
Novavax price target raised to $148 from $88 at Cantor Fitzgerald
MRK Merck
$77.38 /

+0.64 (+0.83%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
SNY Sanofi
$50.96 /

+0.64 (+1.27%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

  • 19
    May
  • 12
    Feb
  • 06
    Feb
  • 10
    Oct
SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SPX S&P 500
$0.00 /

+ (+0.00%)

On The Fly
Fly Intel: After-Hours Movers » 18:58
07/13/20
07/13
18:58
07/13/20
18:58
INMB

INmune Bio

$8.74 /

+1.72 (+24.50%)

, VNDA

Vanda Pharmaceuticals

$11.37 /

-0.125 (-1.09%)

, FREQ

Frequency Therapeutics

$20.43 /

-2.4 (-10.51%)

, EW

Edwards Lifesciences

$67.18 /

-0.67 (-0.99%)

, BA

Boeing

$175.62 /

-2.825 (-1.58%)

, OSMT

Osmotica Pharmaceuticals

$7.71 /

-1.06 (-12.09%)

, ALT

Altimmune

$24.88 /

+2.56 (+11.47%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

06/09/20 Citi
Vanda downgraded to Neutral on FDA dispute at Citi
06/09/20 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
03/16/20
Fly Intel: Top five analyst downgrades
03/16/20 Oppenheimer
Vanda Pharmaceuticals downgraded to Underperform at Oppenheimer on Hetlioz risks
FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

06/05/20 Piper Sandler
Post points to Edwards resuming recruiting for CLASP trial, says Piper Sandler
04/28/20 Wells Fargo
Edwards Lifesciences downgraded on sales growth gap at Wells Fargo
04/28/20 Wells Fargo
Edwards Lifesciences downgraded to Equal Weight from Overweight at Wells Fargo
04/27/20 Barclays
Edwards Lifesciences price target lowered to $155 from $165 at Barclays
BA Boeing
$175.62 /

-2.825 (-1.58%)

07/09/20
Emirates tells Bloomberg Boeing 777X likely to miss 2021 debut
07/08/20 Bernstein
Bernstein downgrades Spirit AeroSystems on slower delivery recovery
06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 RBC Capital
Spirit AeroSystems initiated with an Outperform at RBC Capital
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

07/10/20 SunTrust
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
ALT Altimmune
$24.88 /

+2.56 (+11.47%)

06/01/20 Roth Capital
Altimmune surprises with differentiated T-COVID study, says Roth Capital
05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

  • 14
    Jul
  • 14
    Jul
  • 09
    Jan
  • 03
    Oct
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

Periodicals
American Airlines to warn employees this week of possible furloughs, CNBC says » 18:50
07/13/20
07/13
18:50
07/13/20
18:50
AAL

American Airlines

$11.63 /

-0.3 (-2.51%)

American Airlines intends…

American Airlines intends to warn staff this week about potential furloughs, CNBC's Leslie Josephs reports. The terms of $25B in federal COVID-19 assistance prohibit carriers from laying off workers or lowering their pay rates through September 30, but weak demand is forcing carriers to prepare to cut costs, Josephs says. Reference Link

ShowHide Related Items >><<
AAL American Airlines
$11.63 /

-0.3 (-2.51%)

AAL American Airlines
$11.63 /

-0.3 (-2.51%)

07/09/20 Citi
Citi sees expectations for corporate travel rebound all but evaporating
06/17/20
Fly Intel: Top five analyst initiations
06/17/20 Seaport Global
American Airlines initiated with a Buy at Seaport Global
06/17/20 Cowen
American Airlines price target raised to $20 from $15 at Cowen
AAL American Airlines
$11.63 /

-0.3 (-2.51%)

  • 23
    Jun
AAL American Airlines
$11.63 /

-0.3 (-2.51%)

AAL American Airlines
$11.63 /

-0.3 (-2.51%)

AAL American Airlines
$11.63 /

-0.3 (-2.51%)

Periodicals
American Airlines emphases mask rules following Ted Cruz photo, Reuters says » 18:45
07/13/20
07/13
18:45
07/13/20
18:45
AAL

American Airlines

$11.63 /

-0.3 (-2.51%)

American Airlines said it…

American Airlines said it reached out to U.S. Senator Ted Cruz after a photo of the senator without a mask aboard an aircraft was posted on social media, Reuters' David Shepardson and Tracy Rucinski report. In the photo, the Texas politician can be seem holding a cup of coffee without wearing a mask aboard an airplane, the authors note. American, which requires all passengers to wear masks onboard but lets them take the masks off while eating or drinking, said it had "reached out to Sen. Cruz to affirm the importance of this policy as part of our commitment to protecting the health and safety of the traveling public," the authors say. A spokeswoman for Cruz, Lauren Aronson, said the senator "wears a mask when traveling, and practices social distancing where possible. Consistent with airline policy, he temporarily removes the mask while eating or drinking," according to Reuters. Reference Link

ShowHide Related Items >><<
AAL American Airlines
$11.63 /

-0.3 (-2.51%)

AAL American Airlines
$11.63 /

-0.3 (-2.51%)

07/09/20 Citi
Citi sees expectations for corporate travel rebound all but evaporating
06/17/20
Fly Intel: Top five analyst initiations
06/17/20 Seaport Global
American Airlines initiated with a Buy at Seaport Global
06/17/20 Cowen
American Airlines price target raised to $20 from $15 at Cowen
AAL American Airlines
$11.63 /

-0.3 (-2.51%)

  • 23
    Jun
AAL American Airlines
$11.63 /

-0.3 (-2.51%)

AAL American Airlines
$11.63 /

-0.3 (-2.51%)

AAL American Airlines
$11.63 /

-0.3 (-2.51%)

Periodicals
Google offers to not use Fitbit health data for targeted ads, Reuters says » 18:41
07/13/20
07/13
18:41
07/13/20
18:41
GOOG

Alphabet

$1,511.65 /

-30.41 (-1.97%)

, GOOGL

Alphabet Class A

$1,510.81 /

-29.88 (-1.94%)

, FIT

Fitbit

$6.64 /

-0.175 (-2.57%)

Alphabet's (GOOG)…

Alphabet's (GOOG) Google has offered not to use Fitbit's (FIT) health data to help it target ads in an effort to assuage EU antitrust worries about the proposed $2.1B acquisition of the fitness tracker company, Reuters' Foo Yun Chee reports. "This deal is about devices, not data," Google told Reuters in an emailed statement. Reference Link

ShowHide Related Items >><<
GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

07/13/20 Mizuho
Alphabet price target raised to $1,650 from $1,560 at Mizuho
07/13/20 Barclays
Alphabet price target raised to $1,600 from $1,400 at Barclays
07/09/20 Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
GOOGL Alphabet Class A
$1,510.81 /

-29.88 (-1.94%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

06/19/20 Deutsche Bank
Fitbit acquisition completing remains base case at Deutsche Bank
11/27/19 Deutsche Bank
Second Fitbit suitor should limit downside if deal breaks, says Deutsche Bank
11/06/19 DA Davidson
Sonos rallies after DA Davidson calls 'natural acquisition target' for Apple
11/04/19 DA Davidson
Fitbit downgraded to Neutral from Buy at DA Davidson
GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

GOOGL Alphabet Class A
$1,510.81 /

-29.88 (-1.94%)

GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

GOOGL Alphabet Class A
$1,510.81 /

-29.88 (-1.94%)

GOOG Alphabet
$1,511.65 /

-30.41 (-1.97%)

Upgrade
SKF AB double-upgraded to Buy from Sell at Goldman Sachs » 18:40
07/13/20
07/13
18:40
07/13/20
18:40
SKFRY

SKF AB

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Daniela Costa double-upgraded SKF AB to Buy from Sell with a price target of SEK 214, up from SEK 111. The analyst notes that many investors see short-cycle growth as "likely moderating" from June activity that reflected pent-up levels, but she anticipates further upside ahead as the company speeds up its automation efforts that began in 2017. Costa adds that SKF should be a "major beneficiary" of the cyclical rebound post COVID-10, its valuation is "attractive" at a 27% discount relative to its sector, and the company offers "structural margin upside" for the next 5 years.

ShowHide Related Items >><<
SKFRY SKF AB
$0.00 /

+ (+0.00%)

07/08/20 JPMorgan
SKF AB price target raised to SEK 165 from SEK 160 at JPMorgan
06/26/20 SEB Equities
SKF AB upgraded to Buy from Hold at SEB Equities
06/12/20 Morgan Stanley
SKF AB price target raised to SEK 180 from SEK 130 at Morgan Stanley
06/03/20 Berenberg
SKF AB price target raised to SEK 200 from SEK 190 at Berenberg
Periodicals
White House to soon end audit deal over Chinese listings in U.S., Reuters says » 18:38
07/13/20
07/13
18:38
07/13/20
18:38
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$314.80 /

-2.81 (-0.88%)

, BABA

Alibaba

$251.71 /

-9.27 (-3.55%)

, JD

JD.com

$62.27 /

-3.33 (-5.08%)

, BIDU

Baidu

$127.96 /

-4.42 (-3.34%)

The White House intends…

The White House intends to soon scrap a 2013 pact between U.S. and Chinese auditing authorities, a move that could foreshadow a wider crackdown on U.S.-listed Chinese companies under fire for sidestepping American disclosure rules, Reuters' Humeyra Pamuk and Alexandra Alper report, citing a senior State Department official. Keith Krach, undersecretary for economic growth, energy and the environment, said that a lack of transparency has prompted Trump administration officials to set the stage for exiting the deal soon, the authors say. "The action is imminent," Krach told Reuters in an emailed response to questions. "This is a National Security issue because we cannot continue to afford to put American shareholders at risk, to put American companies at a disadvantage and allow our preeminence of being the gold standard for financial markets to erode." Publicly traded U.S.-listed Chinese firms include Alibaba (BABA), JD.com (JD), and Baidu (BIDU). Reference Link

ShowHide Related Items >><<
SPX S&P 500
$0.00 /

+ (+0.00%)

JD JD.com
$62.27 /

-3.33 (-5.08%)

BIDU Baidu
$127.96 /

-4.42 (-3.34%)

BABA Alibaba
$251.71 /

-9.27 (-3.55%)

SPX S&P 500
$0.00 /

+ (+0.00%)

06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

BABA Alibaba
$251.71 /

-9.27 (-3.55%)

07/09/20
Fly Intel: Top five analyst initiations
07/09/20 Needham
Alibaba initiated with a Buy at Needham
06/19/20 Barclays
Alibaba price target raised to $270 from $260 at Barclays
06/19/20 Morgan Stanley
6.18 promotion in China released pent-up buying demand, says Morgan Stanley
JD JD.com
$62.27 /

-3.33 (-5.08%)

06/30/20 Mizuho
JD.com price target raised to $75 from $62 at Mizuho
06/19/20 Barclays
JD.com price target raised to $65 from $59 at Barclays
06/18/20 Goldman Sachs
JD.com price target raised to $71 from $59 at Goldman Sachs
BIDU Baidu
$127.96 /

-4.42 (-3.34%)

07/02/20 Loop Capital
iQIYI price target raised to $23 from $20 at Loop Capital
06/15/20 Mizuho
Baidu valuation 'compelling' on overstated concerns, says Mizuho
05/20/20 KeyBanc
Baidu price target raised to $145 from $136 at KeyBanc
05/20/20 HSBC
Baidu price target raised to $132 from $120 at HSBC
SPX S&P 500
$0.00 /

+ (+0.00%)

JD JD.com
$62.27 /

-3.33 (-5.08%)

BIDU Baidu
$127.96 /

-4.42 (-3.34%)

BABA Alibaba
$251.71 /

-9.27 (-3.55%)

SPX S&P 500
$0.00 /

+ (+0.00%)

JD JD.com
$62.27 /

-3.33 (-5.08%)

BIDU Baidu
$127.96 /

-4.42 (-3.34%)

BABA Alibaba
$251.71 /

-9.27 (-3.55%)

JD JD.com
$62.27 /

-3.33 (-5.08%)

BIDU Baidu
$127.96 /

-4.42 (-3.34%)

BABA Alibaba
$251.71 /

-9.27 (-3.55%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SPX S&P 500
$0.00 /

+ (+0.00%)

JD JD.com
$62.27 /

-3.33 (-5.08%)

BIDU Baidu
$127.96 /

-4.42 (-3.34%)

BABA Alibaba
$251.71 /

-9.27 (-3.55%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Syndicate
nCino 8.06M share IPO priced at $31.00 » 18:13
07/13/20
07/13
18:13
07/13/20
18:13
NCNO

nCino

$0.00 /

+ (+0.00%)

The deal size was…

The deal size was increased from 7.63M shares to 8.06M shares and priced above the target range of $28.00-$29.00. BofA and Barclays are acting as joint book running managers for the offering.

ShowHide Related Items >><<
  • 14
    Jul
NCNO nCino
$0.00 /

+ (+0.00%)

Hot Stocks
Galera Therapeutics completes enrollment of ph1b/2a clinical trial of GC4419 » 17:47
07/13/20
07/13
17:47
07/13/20
17:47
GRTX

Galera Therapeutics

$7.35 /

+0.22 (+3.09%)

Galera Therapeutics…

Galera Therapeutics announced that it has completed patient enrollment in its pilot Phase 1b/2a safety and anti-cancer efficacy clinical trial of avasopasem manganese in combination with stereotactic body radiation therapy in patients with locally advanced pancreatic cancer. Galera's investigational, highly selective small molecule superoxide dismutase mimetics are designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen. These dismutase mimetics have potential anti-cancer synergy supported by positive results in multiple preclinical models. The randomized Phase 1b/2a trial is evaluating the safety, progression-free survival and overall response rate of GC4419 in combination with SBRT, compared with SBRT and placebo, in LAPC patients. The trial is also assessing safety and tolerability to determine the recommended dose of SBRT when combined with GC4419 or placebo.

ShowHide Related Items >><<
GRTX Galera Therapeutics
$7.35 /

+0.22 (+3.09%)

GRTX Galera Therapeutics
$7.35 /

+0.22 (+3.09%)

12/02/19 BTIG
Galera Therapeutics initiated with a Buy at BTIG
12/02/19 Credit Suisse
Galera Therapeutics initiated with a Neutral at Credit Suisse
12/02/19 Citi
Galera Therapeutics initiated with a Buy at Citi
12/02/19 BofA
Galera Therapeutics initiated with a Buy at BofA/Merrill
GRTX Galera Therapeutics
$7.35 /

+0.22 (+3.09%)

  • 07
    Nov
Conference/Events
Goldman Sachs Global FX analyst to hold analyst/industry conference call » 17:38
07/13/20
07/13
17:38
07/13/20
17:38

Co-Head of Global FX,…

Co-Head of Global FX, Rates & EM Strategy Pandl and Head of US Research Merchandising Hussey provide an FX update: more upside for the Euro and Yuan vs the US dollar on an Analyst/Industry conference call to be held on July 14 at 8 am. Webcast Link

Periodicals
Ford to unveil new Bronco on Monday night, WSJ reports » 17:38
07/13/20
07/13
17:38
07/13/20
17:38
F

Ford

$6.07 /

-0.025 (-0.41%)

, FCAU

Fiat Chrysler

$10.07 /

-0.045 (-0.45%)

For the first time in 24…

For the first time in 24 years, Ford (F) intends to unveil a new Bronco on Monday night, the company's latest attempt to carve into a share of Jeep's (FCAU) dominant position in the off-road sector, the Wall Street Journal's Mike Colias reports. The Bronco would be coming off the sidelines at an interesting time, as U.S. vehicle sales are expected to contract approximately 25% in 2020 largely due to the COVID-19 pandemic, Colias says, citing analyst projections. Reference Link

ShowHide Related Items >><<
FCAU Fiat Chrysler
$10.07 /

-0.045 (-0.45%)

F Ford
$6.07 /

-0.025 (-0.41%)

F Ford
$6.07 /

-0.025 (-0.41%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
Ford price target raised to $7 from $6 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
FCAU Fiat Chrysler
$10.07 /

-0.045 (-0.45%)

06/30/20 UBS
Fiat Chrysler price target raised to EUR 9 from EUR 6 at UBS
06/22/20 Redburn
Fiat Chrysler upgraded to Buy from Neutral at Redburn
FCAU Fiat Chrysler
$10.07 /

-0.045 (-0.45%)

F Ford
$6.07 /

-0.025 (-0.41%)

FCAU Fiat Chrysler
$10.07 /

-0.045 (-0.45%)

F Ford
$6.07 /

-0.025 (-0.41%)

FCAU Fiat Chrysler
$10.07 /

-0.045 (-0.45%)

F Ford
$6.07 /

-0.025 (-0.41%)

FCAU Fiat Chrysler
$10.07 /

-0.045 (-0.45%)

F Ford
$6.07 /

-0.025 (-0.41%)

Conference/Events
Goldman Sachs semiconductors analyst to hold an analyst/industry conference call » 17:33
07/13/20
07/13
17:33
07/13/20
17:33

US Semi Analyst Hari and…

US Semi Analyst Hari and EU Tech Analyst Duval provide an outlook on global semiconductors on an Analyst/Industry conference call to be held on July 14 at 8 am. Webcast Link

Syndicate
Hycroft files to sell 60.9M shares of common stock, 13.5M warrants for holders  17:32
07/13/20
07/13
17:32
07/13/20
17:32
HYMC

Hycroft Mining

$11.05 /

+0.36 (+3.37%)

 
Syndicate
Entera Bio files $100M mixed securities shelf  17:29
07/13/20
07/13
17:29
07/13/20
17:29
ENTX

Entera Bio

$1.84 /

+0.04 (+2.22%)

 
ShowHide Related Items >><<
ENTX Entera Bio
$1.84 /

+0.04 (+2.22%)

Recommendations
Roth Capital positive on Turning Point Therapeutics appointment of Partridge » 17:28
07/13/20
07/13
17:28
07/13/20
17:28
TPTX

Turning Point Therapeutics

$60.02 /

-0.5 (-0.83%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah keeps his Buy rating and $75 price target on Turning Point Therapeutics, saying the company's appointment of Andrew Partridge as Executive VP and Chief Commercial Officer represents a "strong addition to the team". The analyst is positive on the executive's over 20 years of pharmaceutical marketing and sales experience along with a strong track record of global commercial launches and multibillion-dollar marketing operations.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$60.02 /

-0.5 (-0.83%)

TPTX Turning Point Therapeutics
$60.02 /

-0.5 (-0.83%)

07/10/20
Fly Intel: Top five analyst initiations
07/09/20 Oppenheimer
Oppenheimer starts precision oncology 'upstart' Turning Point at Outperform
07/09/20 Roth Capital
Turning Point agreement with Zai Lab favorable, says Roth Capital
07/09/20 Oppenheimer
Turning Point Therapeutics initiated with an Outperform at Oppenheimer
TPTX Turning Point Therapeutics
$60.02 /

-0.5 (-0.83%)

  • 19
    May
  • 06
    Sep
Hot Stocks
Mohawk sinks 10% to $68.64 after announcing Class Action lawsuit  17:26
07/13/20
07/13
17:26
07/13/20
17:26
MHK

Mohawk

$76.59 /

+6.06 (+8.59%)

 
ShowHide Related Items >><<
MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

07/10/20 Jefferies
Mohawk could see short-lived relief rally after flooring data, says Jefferies
07/09/20 Stifel
Stifel says 'difficult if not impossible to opine' on Mohawk allegations
07/09/20 JPMorgan
Allegations in lawsuit to create overhang on Mohawk shares, says JPMorgan
07/09/20 SunTrust
Mohawk quiet period hinders lawsuit response, says SunTrust
MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

MHK Mohawk
$76.59 /

+6.06 (+8.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.